)
Visual21 Oct 2025
Hermès' growth by geographical region visualized
Cyclopharm Limited (CYC) investor relations material
Cyclopharm Limited H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary2 Sep, 2025
Executive summary
Achieved record half-year revenues of $15.42 million, up 26% year-over-year, driven by strong USA TechnegasⓇ sales and significant third-party distribution growth.
USA TechnegasⓇ sales doubled in H1 2025, with installations rising to 35 sites and cumulative sales of $2.06 million since approval.
Major contracts secured with U.S. federal and private healthcare networks, and TechnegasⓇ is now distributed in 66 countries.
Third-party distribution contributed 50% of total revenue, up 58% year-over-year, reflecting strong demand for equipment, consumables, and services.
Cash reserves stood at $12.41 million at June 30, 2025, with an additional $6.2 million expected from a non-core asset sale.
Financial highlights
Total sales revenue reached $15.42 million, up 26% from $12.27 million in the prior year.
USA TechnegasⓇ sales were $1.24 million for the half, with global TechnegasⓇ revenue at $7.66 million.
Third-party distribution revenue was $7.76 million, up 58% year-over-year.
Gross margin was $8.26 million (+20%), with margin percentage declining to 54% from 56% due to product mix.
Net loss after tax was $7.69 million, similar to the prior year, with loss per share improving to (6.96) cents.
Outlook and guidance
Guidance reaffirmed for 250–300 USA TechnegasⓇ installations in 2H CY2026, with expectations for accelerated U.S. growth post-summer.
Recurring revenue from consumables and access fees is expected to become increasingly meaningful as the U.S. footprint expands.
Beyond PE strategy targets expanded use in COPD, asthma, lung cancer, and occupational lung disease, with a total addressable market over US$1.1 billion.
The sales pipeline is robust and materially higher than previous periods, with a focus on converting pre-qualified leads.
How will new sales force convert U.S. pipeline?
What drives U.S. profitability beyond installs?
Which Beyond PE applications show most promise?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cyclopharm Limited earnings date
H2 202522 Feb, 2026
Next Cyclopharm Limited earnings date
H2 202522 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cyclopharm Limited is an Australia-based health technology company primarily engaged in the manufacture and sale of medical equipment and radiopharmaceuticals. The company operates through two main segments: Technegas and Molecular Imaging. The Technegas segment focuses on providing diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. It also distributes products to the diagnostic imaging sector. The Molecular Imaging segment is involved in producing radiopharmaceuticals for the detection of cancer, neurological disorders, and cardiac disease. The company is headquartered in Kingsgrove, New South Wales, and its shares are listed on the ASX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage